SCIENTIFIC REP🔴RTS

2-Oxoesters: A Novel Class of Potent and Selective Inhibitors of Cytosolic Group IVA Phospholipase A$_2$

Maroula G. Kokotou[1,2], Gerasimia Galiatsatou[1], Victoria Magrioti [1], Giorgos Koutoulogenis[1], Efrosini Barbayianni[1], Dimitris Limnios[1,2], Varnavas D. Mouchlis[2], Banita Satpathy[2], Aaron Navratil[2], Edward A. Dennis [2] & George Kokotos [1]

Cytosolic phospholipase A$_2$ (GIVA cPLA$_2$) is the only PLA$_2$ that exhibits a marked preference for hydrolysis of arachidonic acid containing phospholipid substrates releasing free arachidonic acid and lysophospholipids and giving rise to the generation of diverse lipid mediators involved in inflammatory conditions. Thus, the development of potent and selective GIVA cPLA$_2$ inhibitors is of great importance. We have developed a novel class of such inhibitors based on the 2-oxoester functionality. This functionality in combination with a long aliphatic chain or a chain carrying an appropriate aromatic system, such as the biphenyl system, and a free carboxyl group leads to highly potent and selective GIVA cPLA$_2$ inhibitors (X_I(50) values 0.00007–0.00008) and docking studies aid in understanding this selectivity. A methyl 2-oxoester, with a short chain carrying a naphthalene ring, was found to preferentially inhibit the other major intracellular PLA$_2$, the calcium-independent PLA$_2$. In RAW264.7 macrophages, treatment with the most potent 2-oxoester GIVA cPLA$_2$ inhibitor resulted in over 50% decrease in KLA-elicited prostaglandin D$_2$ production. The novel, highly potent and selective GIVA cPLA$_2$ inhibitors provide excellent tools for the study of the role of the enzyme and could contribute to the development of novel therapeutic agents for the treatment of inflammatory diseases.

In mammals, the phospholipase A$_2$ (PLA$_2$) superfamily consists of six types of diverse enzymes: GIV PLA$_2$ [cytosolic PLA$_2$ (cPLA$_2$)], GVI PLA$_2$ [calcium-independent PLA$_2$ (iPLA$_2$)], several groups of secreted PLA$_2$ (sPLA$_2$), two groups of platelet-activating factor-acetylhydrolases PLA$_2$ (PAF-AHs), GXV PLA$_2$ (lysosomal PLA$_2$), and GXVI PLA$_2$ (adipose PLA$_2$)[1]. Among all these enzymes, cPLA$_2$ is the only PLA$_2$ that exhibits a marked preference for hydrolysis of arachidonic acid at the *sn*-2 position of phospholipid substrates[2]. The activation of cPLA$_2$ results in the production of arachidonic acid and lysophospholipids giving rise to the generation of diverse lipid mediators, such as leukotrienes, prostaglandins, lysophosphatidic acid etc[3]. Since many of them are involved in the response to inflammation, the regulation of cPLA$_2$ is of great importance in chronic inflammatory conditions[1, 4]. In a recent review article, Leslie has summarized the physiological function and the role of cPLA$_2$ in diseases[5]. The most recent studies on inherited GIVA cPLA$_2$ deficiency demonstrate the fundamental role of this enzyme in eicosanoid formation and cellular responses in human circulation[6].

It was thirty years ago, when the first cytosolic PLA$_2$ activity (now attributed to GIVA cPLA$_2$ or cPLA$_2\alpha$) was reported in human neutrophils and platelets[7, 8]. The purification, sequence, and cloning of the first human cPLA$_2$ was reported in 1991[9, 10]. GIVA cPLA$_2$ contains 749 amino acids, is an 85 kDa protein, and consists of an N-terminal C2 domain and a C-terminal catalytic domain. The crystal structure of GIVA cPLA$_2$ was solved by Dessen *et al*. in 1999[11]. The catalytic domain of GIVA cPLA$_2$ utilizes an unusual catalytic dyad, Ser-228/Asp-549, located in the α/β hydrolase domain, to catalyze the hydrolysis of the substrate phospholipid[12, 13].

[1]Laboratory of Organic Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, Panepistimiopolis, Athens, 15771, Greece. [2]Department of Chemistry and Biochemistry and Department of Pharmacology, School of Medicine, University of California, San Diego, La Jolla, California, 92093-0601, USA. Correspondence and requests for materials should be addressed to E.A.D. (email: edennis@ucsd.edu) or G.K. (email: gkokotos@chem.uoa.gr)

Figure 1. Common inhibitors of phospholipases A_2.

The diverse bioactive lipids produced by the $cPLA_2$ activity regulate normal physiological processes and disease pathogenesis, and as a consequence, great attention has been given to the development of selective GIVA $cPLA_2$ inhibitors. The structural diversity of the synthetic inhibitors is summarized in a number of review articles[1,14–16]. The first synthetic inhibitor of GIVA $cPLA_2$ was an arachidonic acid derivative, arachidonoyl trifluoromethyl ketone, containing an activated carbonyl functionality[17]. Shionogi developed a series of pyrrolidine-based inhibitors, including pyrrophenone (**1**, Fig. 1), following a high throughput screening approach[18, 19]. Wyeth has expended major efforts to develop novel indole-based inhibitors, for example, ecopladib (**2a**, Fig. 1), efipladib (**2b**, Fig. 1) and giripladib (**2c**, Fig. 1) as novel therapeutics for inflammatory diseases[20–23]. Giripladib was the most promising among them as it was advanced into a Phase II clinical trial for osteoarthritis, however in 2007 the trial was terminated due to gastrointestinal side effects[24]. A structurally related GIVA $cPLA_2$ inhibitor is currently on phase I/II clinical study in healthy volunteers and patients with moderate to severe dermatitis and the estimated date of completion is June 2017[25]. Our groups have designed and developed long chain 2-oxoamides based on unnatural amino acids, for example compound **3**, as GIVA $cPLA_2$ inhibitors[26–31]. Lehr and coworkers studied a variety of activated carbonyl-based indol-1-yl-propan-2-ones, for example compound **4** (Fig. 1) containing a variety of substituents on the heterocyclic ring to optimize the enzyme-inhibitor binding[32–36]. Recently, we have reported the new thiazolyl ketone GK470[37] (**5**, Fig. 1) as a GIVA $cPLA_2$ inhibitor, while Tomoo and colleagues demonstrated a new series of indole-based inhibitors, such as inhibitor **6**[38].

To fully understand the role that each particular PLA_2 type plays in physiological and pathological conditions, and to develop new candidates for the treatment of various inflammatory diseases, potent and selective GIVA $cPLA_2$ inhibitors are needed. In this work, we present a novel class of potent and selective GIVA $cPLA_2$ inhibitors and our studies on their synthesis and study of their *in vitro* inhibitory potency and selectivity.

Results

Design and synthesis of inhibitors.
Upon activation by intracellular calcium binding to the C2 domain of GIVA $cPLA_2$, the enzyme is translocated to the surface of the phospholipid membrane where it extracts a single

Figure 2. Design of 2-oxoesters.

phospholipid substrate into the active site[39, 40]. Then, the catalytic active site serine attacks the ester bond of the phospholipid substrate initiating the hydrolysis step. A number of the existing potent GIVA cPLA$_2$ inhibitors, for example arachidonoyl trifluoromethyl ketone[17], 2-oxoamides[26–31], indolyl-propanones[32–36], thiazolyl ketones[37] contain an activated carbonyl group able to interact with the active site serine. In our quest for novel potent and selective GIVA cPLA$_2$ inhibitors, we envisaged that the 2-oxoester (or α-keto ester) functionality could serve as such an activated carbonyl group. In 1990, it was demonstrated that α-keto ester derivatives of *N*-protected amino acids and peptides inhibit serine and cysteine proteinases[41], while peptidyl α-keto esters inhibit the serine proteases porcine pancreatic elastase and human neutrophil elastase[42]. Later on, various peptide α-keto-esters and α-keto acids were reported as inhibitors of calpains and other cysteine proteases[43] and of hepatitis C virus NS3 protease[44]. It is quite clear that a potential GIVA cPLA$_2$ inhibitor, in addition to a functionality targeting the active site serine, should contain a lipophilic chain able to mimic the interactions of the substrate arachidonoyl chain with the lipophilic binding site of the enzyme. In addition, a free carboxyl group may contribute significantly to the overall binding of the inhibitor to the enzyme. As we have proposed in the past[26], and according to the results of our mechanistic studies using a combination of hydrogen-deuterium exchange mass spectrometry with molecular dynamics simulations[31], such a carboxyl group may interact with the side chain of the enzyme residue Arg-200. Taken together, we designed compounds containing a 2-oxoester functionality, a lipophilic chain and a free carboxyl group (Fig. 2).

A variety of 2-hydroxy acids, required for the synthesis of 2-oxoesters, were synthesized as described in Fig. 3. Aldehydes **7a-d** were converted into cyanohydrins **8a-d** and consequently to 2-hydroxy methyl esters **9a-d** by treatment with HCl in methanol. 2-Hydroxy acids **11a-d** were obtained by alkaline hydrolysis of **9a-d**. In addition, 2-hydroxy methyl esters **9a,b,e** were oxidized to the corresponding 2-oxoesters **10a,b,e** (Fig. 3). Free 2-oxohexadecanoic acid **12e** was synthesized by mild alkaline hydrolysis of **10e** using aqueous Cs$_2$CO$_3$ in methanol, as depicted in Fig. 3.

The general route for the synthesis of the designed 2-oxoesters carrying a free carboxyl group is quite straightforward and is depicted in Fig. 4. The key-step was the reaction between the cesium salt of the appropriate 2-hydroxy acids **11a, 11c, 11d** and **13a,b** with omega-bromo esters **14a,b**. The resulting 2-hydroxy esters **15a-h** ware then oxidized to the corresponding 2-oxoesters **16a-h** using preferably the Dess-Martin periodinane reagent[45]. Removal of the *tert*-butyl ester protecting group under acidic conditions led to the target compounds **17a-h**.

2-Oxoester **19** carrying an ethyl ester group and 2-hydroxyester **20** carrying a free carboxyl group were synthesized as depicted in Fig. 5.

In vitro inhibition of GIVA cPLA$_2$, GVIA iPLA$_2$ and GV sPLA$_2$.

All synthesized 2-oxoesters were tested for their *in vitro* activity on recombinant human GIVA cPLA$_2$ using mixed micelle assays. In addition, their selectivity over human GVIA iPLA$_2$ and GV sPLA$_2$ was also studied using group specific mixed micelle assays. The activity of these PLA$_2$s was tested on mixed-micelles containing 100 μM PAPC and 400 μM Triton-X.

The *in vitro* inhibition of human GIVA cPLA$_2$, GVIA iPLA$_2$ and GV sPLA$_2$ was carried out using previously described mixed micelle-based assays[27, 28, 30]. The inhibition results are presented in Table 1, either as percent inhibition or as $X_I(50)$ values. At first, the percent of inhibition for each PLA$_2$ enzyme at 0.091 mole fraction of each inhibitor was determined. Then, the $X_I(50)$ values were measured for compounds that displayed greater than 95% inhibition of GIVA cPLA$_2$. The $X_I(50)$ is the mole fraction of the inhibitor in the total substrate interface required to inhibit the enzyme activity by 50%.

Representative curves for the concentration dependence of the inhibition of GIVA cPLA$_2$ by 2-oxoesters **17a**, **17b** and **17d** were fit to sigmoidal curves and are presented in Fig. 6.

Discussion

Methyl 2-oxopalmitate **10e** (entry 1, Table 1) weakly inhibited, at a high concentration, both the intracellular enzymes GIVA cPLA$_2$ and GVIA iPLA$_2$. However, 2-oxopalmitic acid **12e** (entry 2, Table 1) inhibited weakly, but selectively, GIVA cPLA$_2$. Interestingly, when the 2-oxoester functionality was combined with a long aliphatic chain together with a free carboxyl group at a distance of three carbon atoms, potent inhibition of GIVA cPLA$_2$ was observed and the inhibitor **17a** (GK161) showed a $X_I(50)$ value of 0.00008 (entry 3, Table 1). In addition, this inhibitor was selective and did not inhibit the activities of GVIA iPLA$_2$ and the secreted GV sPLA$_2$. This selectivity is in agreement with our previous observations that 2-oxoamides containing a free carboxyl group selectively inhibit GIVA cPLA$_2$[28, 30]. Given that for the most potent 2-oxoamides present $X_I(50)$ values are not lower than 0.003[30], the present 2-oxoester was proven to be a much more potent inhibitor of GIVA cPLA$_2$. The corresponding 2-hydroxy ester derivative **20** did not present any inhibition of either GIVA cPLA$_2$ or GVIA iPLA$_2$ (entry 4, Table 1), demonstrating the importance of the oxoester functionality for the inhibition.

When the long aliphatic chain was replaced by a chain of a similar size containing an aromatic ring, the inhibitory activity over GIVA cPLA$_2$ was considerably reduced (entry 5, Table 1). Compounds **16c** and **19** containing a medium chain carrying an aromatic ring and a protected carboxyl group (either ethyl ester or *tert*-butyl ester) totally abolished any inhibitory activity (entries 6 and 7, Table 1). In accord with our expectation, the replacement

Figure 3. Synthesis of 2-hydroxy acids and 2-oxoacids. (**a**) (i) aq. sol. NaHSO$_3$, CH$_2$Cl$_2$, (ii) KCN, H$_2$O; (**b**) 4 N HCl/CH$_3$OH; (**c**) Dess-Martin periodinane reagent, dry CH$_2$Cl$_2$; (**d**) NaOH 1 N, CH$_3$OH; (**e**) 20% aq. sol. Cs$_2$CO$_3$, CH$_3$OH.

of the long aliphatic chain by a more drug-like chain of four carbon atoms carrying a biphenyl system led again to a potent and selective inhibition of GIVA cPLA$_2$ (entry 8, Table 1). Inhibitor **17d** (GK200) was found to be eight times less potent than **17a** showing a $X_I(50)$ value of 0.00068. To extend the structure-activity relationship studies, we either increased the distance between the free carboxyl group and the oxoester functionality or decreased the distance between the aromatic rings and the oxoester functionality. Inhibitor **17e** (GK433) proved to be highly potent, slightly better than **17a**, presenting a $X_I(50)$ value of 0.00007 (entry 9, Table 1). The importance of the four-carbon atoms distance between the free carboxyl group and the oxoester functionality was clearly demonstrated by the inhibitor **17f** (GK452), which presented highly potent inhibition of GIVA cPLA$_2$ with a $X_I(50)$ value of 0.000078 (entry 10, Table 1). Decrease of the distance between the biphenyl aromatic system and the oxoester functionality (compounds **17g** and **17h**) resulted in considerable reduction of the potency (entries 11 and 12, Table 1). All the highly potent GIVA cPLA$_2$ inhibitors **17a**, **17d**, **17e** and **17f** presented selectivity, because none of them exhibited any appreciable inhibition of GVIA iPLA$_2$. In addition, none of the synthesized and tested 2-oxoesters inhibited GV sPLA$_2$.

Since both the intracellular enzymes GIVA cPLA$_2$ and GVIA iPLA$_2$ are serine hydrolases and both utilize a catalytic dyad in their catalytic mechanism, it is likely that cross reactivity may be observed for inhibitors designed to carry a functionality targeting the active site serine. Indeed, such cross reactivity has been observed for several

Figure 4. Synthesis of 2-oxoesters. (**a**) i. 20% aq. sol. Cs_2CO_3, THF, H_2O, ii. $Br(CH_2)_nCH_2CH_2COOBu^t$, DMF, reflux overnight; (**b**) Dess-Martin periodinane reagent, dry CH_2Cl_2; (**c**) 50% CF_3COOH in CH_2Cl_2.

Figure 5. Synthesis of compounds **19** and **20**. (**a**) i. 20% aq. sol. Cs_2CO_3, THF, H_2O, ii. $BrCH_2CH_2CH_2COOEt$, DMF, reflux overnight; (**b**) Dess-Martin periodinane reagent, dry CH_2Cl_2; (**c**) 50% CF_3COOH in CH_2Cl_2.

inhibitors containing an activated carbonyl group initially developed to target GIVA cPLA$_2$. For example, arachidonoyl trifluoromethyl ketone was found to inhibit not only GIVA cPLA$_2$, but also GVIA iPLA$_2$. It is apparent that the presence of other groups able to develop appropriate hydrophobic and/or hydrophilic interactions contributes to the overall binding of the inhibitor to the enzyme, determining the inhibitory selectivity over GIVA cPLA$_2$ or GVIA iPLA$_2$. We have previously shown that pentafluoroethyl or trifluoromethyl ketones of a four-carbon atom chain carrying an aromatic ring are selective inhibitors of GVIA iPLA$_2$[46–48]. Inspired by the structures of FKGK11[46] and FKGK18[47], we designed simple methyl 2-oxoesters with a linker of four methylene groups between the activated carbonyl group and the aromatic ring. Unfortunately, compound **10a** (entry 13, Table 1) carrying a phenyl ring only weakly inhibited GVIA iPLA$_2$ at a high concentration. On the contrary, compound **10b** (GK451)

Entry	No	Structure	GIVA cPLA$_2$ % Inhibition[a]	GIVA cPLA$_2$ $X_I(50)$	GVIA iPLA$_2$ % Inhibition[a]	GVIA iPLA$_2$ $X_I(50)$	GV sPLA$_2$ % Inhibition[a]	ClogP
1	10e		68.2 ± 2.7		69.4 ± 12.2		27.5 ± 0.9	6.51
2	12e		78.4 ± 3.5		<25		<25	5.63
3	17a		>95	0.00008 ± 0.00001	<25		<25	6.76
4	20		<25		<25		41.0 ± 0.2	6.82
5	17b		>95	0.00289 ± 0.00043	<25		52.6 ± 5.3	5.46
6	16c		<25		<25		<25	4.58
7	19		27.3 ± 4.8		<25		<25	3.87
8	17d		>95	0.00068 ± 0.00007	<25		<25	4.78
9	17e		>95	0.00007 ± 0.00001	25		<25	6.68
10	17f		>95	0.000078 ± 0.00001	65 ± 3.4		<25	4.70
11	17g		>95	0.0065 ± 0.002	84 ± 1.5		<25	4.25
12	17h		>95	0.0010 ± 0.0003	94 ± 1.4		<25	4.17
13	10a		<25		72 ± 4		<25	
14	10b		55 ± 4.0		>95	0.0052 ± 0.0007	<25	3.81
Continued								

Entry	No	Structure	GIVA cPLA$_2$		GVIA iPLA$_2$		GV sPLA$_2$	
			% Inhibition[a]	X_I(50)	% Inhibition[a]	X_I(50)	% Inhibition[a]	ClogP
15	4		>95	0.00008 ± 0.000005^c				8.50

Table 1. *In vitro* inhibitory potency and selectivity of 2-oxoesters. [a]% Inhibition at 0.091 mole fraction of each inhibitor. [b]IC$_{50}$ 4.3 nM in a vesicle assay[32].

(entry 14, Table 1) carrying a naphthalene ring presented interesting inhibition of GVIA iPLA$_2$ with a X_I(50) value of 0.0052. At the same time, it presents selectivity, because it only weakly inhibits GIVA cPLA$_2$ at a high concentration (55% at 0.091 mole fraction), while it does not inhibit at all GV sPLA$_2$.

To better understand the interaction of 2-oxoesters with GIVA cPLA$_2$ and GVIA iPLA$_2$, the most potent GIVA cPLA$_2$ inhibitor **17f** was docked in the active site of either GIVA cPLA$_2$ or GVIA iPLA$_2$. For the docking calculations, the structures of GIVA cPLA$_2$ and GVIA iPLA$_2$ with two different fluoroketone compounds in the active site were used (GK174: orange color in Fig. 7a and FKGK18: magenta color in Fig. 7b). The binding mode of these two fluoroketones was validated using H/D exchange and MD simulations in a previously published study[49]. A theoretical score of 10.2 kcal/mol indicated that **17f** is a tight binder for GIVA cPLA$_2$. The oxoester moiety forms hydrogen-bonding with the oxyanion hole (Gly197/Gly198), while the carboxylic moiety interacts with Arg200, which was found to stabilize the phosphate group of a phospholipid substrate molecule[39]. Compared to GK174 (orange color in Fig. 7a) the addition of the carboxylic moiety is responsible for increasing the potency of **17f** by 10-fold. This compound exhibits no activity towards GVIA iPLA$_2$ and it received a low theoretical binding score of 6.3 kcal/mol indicating that is a weak binder. Compared to fluoroketone FKGK18 (magenta color in Fig. 7b) the addition of the carboxylic moiety increases the size of the compound and it cannot be accommodated in the active site of GVIA iPLA$_2$.

All the above data, clearly demonstrate that 2-oxoesters consisting of a quite long chain (aliphatic or incorporating aromatic systems like the biphenyl system) in combination with a free carboxyl group at a distance of four or three carbon-atoms from the oxoester functionality are highly potent and selective inhibitors of GIVA cPLA$_2$. Decreasing the size of the synthetic compound and eliminating the free carboxyl group may change the selectivity. Indeed, a methyl 2-oxoester based on a short chain carrying a naphthalene ring was found to inhibit preferentially GVIA iPLA$_2$. In other words, it seems that the selectivity of compounds based on the 2-oxoester functionality may be tuned choosing the structural features that ensure the appropriate interactions with each enzyme (either GIVA cPLA$_2$ or GVIA iPLA$_2$).

To compare our novel highly potent 2-oxoester inhibitors of GIVA cPLA$_2$ with the existing inhibitors, we studied the benchmark GIVA cPLA$_2$ inhibitor **4** in our mixed-micelle assay. This inhibitor, developed by Lehr[32], is the most potent inhibitor in the literature presenting an IC$_{50}$ value of 4.3 nM in a vesicle assay[32]. In the mixed micelle assay, it was proved equipotent with oxoester **17a** with a X_I(50) value of 0.00008 (entry 15, Table 1). In addition, several 2-oxoesters were found to be more potent than the other benchmark GIVA cPLA$_2$ inhibitor **1** (pyrrophenone), which presents an X_I(50) value of 0.002[26, 27]. Another important property of a GIVA cPLA$_2$ inhibitor, is the ClogP value, which is a measure of the hydrophobicity. ClogP represents the calculated partition coefficient in octanol/water on a logarithmic scale. Usually, GIVA cPLA$_2$ inhibitors suffer from high lipophilicity. For example, the ClogP value of inhibitor **4** is 8.50, while pyrrophenone **1** and giripladib **2c** present high lipophilicities too (ClogP 8.29 and 10.75, respectively). Inhibitors with such high values are not expected to present favorable ADME properties according to Lipinski's rule of five[50]. Although 2-oxoesters **17a** and **17e** contain a long aliphatic chain, they present lower lipophilicity (ClogP 6.76 and 6.68, respectively), while the 2-oxoesters **17d** and **17f** carrying the biphenyl system have considerably lower ClogP values (4.78 and 4.70, respectively). The logP value of **17f**, measured by HPLC, was found 3.5. Thus, the lipophilicity of **17f** is encouraging and this inhibitor is the first example of a highly potent GIVA cPLA$_2$ inhibitor, which presents a ClogP value lower than 5.

The cellular effect of the most potent GIVA cPLA$_2$ inhibitor **17f** on eicosanoid biosynthesis was studied in macrophages. RAW264.7 macrophages were used as a model system to determine if **17f** displays inhibitory activity toward GIVA cPLA$_2$ *in vivo*. It is well established that the toll-like receptor 4 (TLR4)-specific agonist Kdo2-lipid A (KLA) leads to GIVA cPLA$_2$ activation[51, 52] and release of arachidonic acid in macrophages that is then converted into eicosanoids by cyclooxygenase-2[53–55]. Previous work has demonstrated that the major eicosanoid produced by KLA stimulated RAW264.7 macrophages is prostaglandin D$_2$ (PGD$_2$)[56]. The high levels of PGD$_2$ compared to background in culture supernatants following KLA stimulation makes it an ideal marker for GIVA cPLA$_2$ activity in macrophages. Inhibitor **17f** did not show cellular toxicity at any concentrations tested as measured by trypan blue exclusion (data not shown). RAW264.7 macrophages were pre-treated with vehicle control, DMSO or **17f** (5 μM) for one hour prior to stimulation with KLA (100 ng/mL). Culture supernatants were collected after 24 hours for eicosanoid quantification by LC-MS/MS. Treatment with inhibitor **17f** resulted in over 50% decrease in KLA-elicited PGD$_2$ production by macrophages (Fig. 8). A similar reduction in other minor products including PGE$_2$, PGF$_{2\alpha}$, 11-HETE and 15-HETE was observed (data not shown), suggesting that the inhibition was not specific to PGD$_2$. This data is consistent with **17f** inhibition of GIVA cPLA$_2$ in living cells.

Figure 6. Inhibition curves for **17a**, **17b** and **17d**. The curves were generated using GraphPad Prism with a nonlinear regression targeted at symmetrical sigmoidal curves based on plots of % inhibition versus log(inhibitor concentration). The reported $X_I(50)$ values were calculated from the resultant plots.

In conclusion, we describe a novel class of GIVA cPLA$_2$ inhibitors based on the 2-oxoester functionality. This reactive functionality in combination with a long aliphatic chain or a chain carrying an appropriate aromatic system, such as the biphenyl system, and a free carboxyl group leads to highly potent and selective GIVA cPLA$_2$ inhibitors. Inhibitors **17a**, **17e** and **17f** present $X_I(50)$ values of 0.00007–0.00008 and are equipotent to the most potent known GIVA cPLA$_2$ inhibitor. In particular, inhibitors incorporating the biphenyl system, like **17f**, present interesting favorable lipophilicity (ClogP values lower than 5). The novel highly potent and selective GIVA cPLA$_2$ inhibitors may be excellent tools for the study of the role of the enzyme in cells and in animals and may contribute to the development of novel medicinal agents for the treatment of inflammatory diseases.

Methods

General.   Chromatographic purification of products was accomplished using Merck Silica Gel 60 (70–230 or 230–400 mesh). Thin-layer chromatography (TLC) was performed on Silica Gel 60 F254 aluminum plates. TLC pots were visualized with UV light and/or phosphomolybdic acid in EtOH. Melting points were determined using a Büchi 530 apparatus and were uncorrected. ^{1}H and ^{13}C NMR spectra were recorded on a Varian Mercury (200 MHz and 50 MHz respectively) in CDCl$_3$. Chemical shifts are given in ppm, and coupling constants (J) in Hz. Peak multiplicities are described as follows: s, singlet, d, doublet, t, triplet and m, multiplet. Electron spray ionization (ESI) mass spectra were recorded on a Finnigan, Surveyor MSQ Plus spectrometer. Dichloromethane was dried by standard procedures and stored over molecular sieves. All other solvents and chemicals were reagent grade and used without further purification. The purity of all compounds subjected to biological tests was determined by analytical HPLC, and was found to be ≥95%. HPLC analyses were carried out on a Shimadzu LC-2010AHT system and a Merck Chromolith Performance (100 × 4.6 mm) analytical column, using H$_2$O/MeOH 10/90 v/v, at a flow rate of 1.0 mL/min. HRMS spectra were recorded on a Bruker Maxis Impact QTOF Spectrometer.

Compounds **8a**[57], **8b**[57], **9e**[58], **11a**[57], **11b**[57], **13a**[59], **13b**[60] have been described elsewhere and their analytical data are in accordance with literature.

Synthesis of cyanohydrins 8c,d.   To a stirred solution of aldehyde **7c,d** (1.0 mmol) in CH$_2$Cl$_2$ (1.4 mL), an aqueous solution of NaHSO$_3$ (0.25 mL, 1.5 mmol) was added and the mixture was stirred for 30 min at room temperature. The organic solvent was evaporated under reduced pressure and H$_2$O (1 mL) was added. The mixture was cooled to 0 °C and an aqueous solution of KCN (0.25 mL, 1.5 mmol) was added within 2 h under vigorous stirring. The reaction was stirred for 18 h at room temperature and then, water (10 mL) was added and extracted with CH$_2$Cl$_2$ (3 × 10 mL). The combined organic phases was washed with brine (30 mL), dried over Na$_2$SO$_4$ and evaporated under reduced pressure. The residue was purified by flash column chromatography [ethyl acetate (EtOAc)/petroleum ether (bp 40–60 °C), 2:8].

6-([1,1′-Biphenyl]-4-yl)-2-hydroxyhexanenitrile (8c).   Yield 80%; White solid; mp: 85–87 °C; ^{1}H NMR (200 MHz, CDCl$_3$): δ 7.67–7.14 (m, 9 H), 4.45 (t, J = 6.9 Hz, 1 H), 3.90 (br s, 1 H), 2.69 (t, J = 7.1 Hz, 2 H), 1.89 (q, J = 7.2 Hz, 2 H), 1.79–1.39 (m, 4 H); ^{13}C NMR (50 MHz, CDCl$_3$): δ 141.0, 140.9, 138.8, 129.0, 128.7, 127.0, 126.9, 126.5, 119.9, 61.1, 35.2, 34.9, 30.6, 24.2; MS (m/z, ESI): [M + NH$_4$]$^+$ calcd. for C$_{18}$H$_{19}$NO, 283.2; found, 283.3; analysis (calcd., found for C$_{18}$H$_{19}$NO): C (81.47, 81.18), H (7.22, 7.41), N (5.28, 5.33).

5-([1,1′-Biphenyl]-4-yl)-2-hydroxypentanenitrile (8d).   Yield 76%; White solid; mp: 80–82 °C; ^{1}H NMR (200 MHz, CDCl$_3$): δ 7.64–7.23 (m, 9 H), 4.48 (t, J = 6.9 Hz, 1 H), 3.80 (br s, 1 H), 2.64 (t, J = 7.0 Hz, 2 H), 1.84 (q, J = 7.0 Hz, 2 H), 1.69–1.57 (m, 2 H); ^{13}C NMR (50 MHz, CDCl$_3$): δ 141.3, 140.8, 138.4, 129.1, 128.7, 127.6, 127.2, 126.8, 118.5, 61.9, 35.1, 34.5, 23.8; MS (m/z, ESI): [M + NH$_4$]$^+$ calcd. for C$_{17}$H$_{17}$NO 269.2; found, 269.2; analysis (calcd., found for C$_{17}$H$_{17}$NO): C (81.24, 81.02), H (6.82, 6.99), N (5.57, 5.69).

Synthesis of 2-hydroxy esters 9a-d.   Cyanohydrin **8a-d** (1 mmol) was dissolved in methanolic solution of HCl (10 mL, 4 N) and the reaction mixture was stirred for 24 h at room temperature. The organic solvent was evaporated *in vacuo* and the remaining solid was dissolved in diethyl ether (10 mL) and re-evaporated.

Figure 7. Binding mode of inhibitor **17f** in the active site of (**a**) GIVA cPLA$_2$ and (**b**) GVIA iPLA$_2$.

Figure 8. Inhibitor **17f** inhibits KLA-elicited prostaglandin D$_2$ biosynthesis by macrophages. Macrophages were pre-treated with media (control), vehicle control (DMSO, 0.1%) or inhibitor **17f** (5 μM) 1 hr before KLA (100 ng/mL, ■) or mock (□) treatment. Supernatants were collected 24 hr following stimulation for eicosanoid quantification. Graph displays the mean ± SEM of a single experiment containing technical duplicates that is representative of 2 independent experiments. * indicates statistical difference compared to KLA treatment (P ≤ 0.05).

Dilution and evaporation was repeated twice. Then, the product was purified by flash column chromatography [EtOAc-petroleum ether (bp 40–60 °C), 2:8].

Methyl 2-hydroxy-6-phenylhexanoate (9a). Yield 61%; Yellow oil; ^{1}H NMR (200 MHz, CDCl$_3$): δ 7.37–7.04 (m, 5 H), 4.23–4.10 (m, 1 H), 3.77 (s, 3 H), 2.74 (br s, 1 H), 2.62 (t, J = 7.1 Hz, 2 H), 1.92–1.25 (m, 6 H); ^{13}C NMR (50 MHz, CDCl$_3$): δ 175.7, 142.3, 128.3, 128.2, 125.6, 70.3, 52.4, 35.7, 34.1, 31.1, 24.4; MS (m/,z ESI): [M + NH$_4$]$^+$ calcd. for C$_{13}$H$_{18}$O$_3$ 240.2 found, 240.2; analysis (calcd., found for C$_{13}$H$_{18}$O$_3$): C (70.24, 70.01), H (8.16, 8.29).

Methyl 2-hydroxy-6-(naphthalen-2-yl)hexanoate (9b). Yield 73%; Colorless oil; ^{1}H NMR (200 MHz, CDCl$_3$): δ 7.90–7.20 (m, 7 H), 4.30–4.02 (m, 1 H), 3.76 (s, 3 H), 3.35 (br s, 1 H), 2.97–2.75 (m, 2 H), 1.97–1.34 (m, 6 H); ^{13}C NMR (50 MHz, CDCl$_3$): δ 175.6, 139.8, 133.5, 127.7, 127.5, 127.3, 127.2, 126.2, 125.8, 125.0, 70.3, 52.4,

35.8, 34.1, 30.9, 24.4; MS (m/z, ESI): [M + Na]$^+$ calcd. for $C_{17}H_{20}O_3$ 295.1, found, 295.2; analysis (calcd., found for $C_{17}H_{20}O_3$): C (74.97, 74.72), H (7.40, 7.62).

Methyl 6-([1,1′-biphenyl]-4-yl)-2-hydroxyhexanoate (9c).   Yield 69%; Colorless oil; ^{1}H NMR (200 MHz, CDCl$_3$): δ 7.70–7.06 (m, 9 H), 4.45 (t, J = 7.0 Hz, 1 H), 3.79 (s, 3 H), 3.00 (br s, 1 H), 2.69 (t, J = 7.1 Hz, 2 H), 1.89 (q, J = 7.5 Hz, 2 H), 1.79–1.36 (m, 4 H); ^{13}C NMR (50 MHz, CDCl$_3$): δ 175.7, 141.0, 140.9, 138.7, 129.0, 128.7, 127.0, 126.9, 70.4, 52.5, 35.2, 34.9, 30.7, 24.2; MS (m/z, ESI): [M + Na]$^+$ calcd. for $C_{19}H_{22}O_3$ 321.1, found, 321.2; analysis (calcd., found for $C_{19}H_{22}O_3$): C (80.82, 80.61), H (7.85, 7.98).

Methyl 5-([1,1′-biphenyl]-4-yl)-2-hydroxypentanoate (9d).   Yield 71%; Colorless oil; ^{1}H NMR (200 MHz, CDCl$_3$): δ 7.69–7.18 (m, 9 H), 4.40 (t, J = 6.9 Hz, 1 H), 3.76 (s, 3 H), 3.54 (brs, 1 H), 2.65 (t, J = 7.1 Hz, 2 H), 1.84 (q, J = 7.1 Hz, 2 H), 1.64–1.36 (m, 2 H); ^{13}C NMR (50 MHz, CDCl$_3$): δ 176.1, 141.3, 140.8, 138.2, 129.0, 128.9, 127.5, 127.0, 126.8, 70.3, 52.3, 35.5, 34.9, 24.4; MS (m/z, ESI): [M + Na]$^+$ calcd. for $C_{18}H_{20}O_3$ 307.1, found, 307.2; analysis (calcd., found for $C_{18}H_{20}O_3$): C (76.03, 75.83), H (7.09, 7.27).

Synthesis of 2-oxoesters 10α, 10b, 10e, 16a-h, 19.   To a stirred solution of 2-hydroxy esters **9a, 9b, 9e, 15a-h, 18** (1 mmol) in dry CH_2Cl_2 (10 mL) was added Dess-Martin periodinane (1.1 mmol, 0.47 g) and the reaction mixture was stirred for 1.5 h at room temperature. Then, CH_2Cl_2 (5 mL) was added and the organic phase was washed with a mixture of $Na_2S_2O_3$ 10% and $NaHCO_3$ 10% (15 mL, 1:1, v/v). The aqueous phase was washed with CH_2Cl_2 (15 mL) and all the organic phases were collected, dried (Na_2SO_4) and evaporated under reduced pressure. The residue was purified by flash column chromatography [EtOAc-petroleum ether (bp 40–60 °C), 2:8].

Methyl 2-oxo-6-phenylhexanoate (10a, GK437).   Yield 66%; Colorless oil; ^{1}H NMR (200 MHz, CDCl$_3$): δ 7.40–7.08 (m, 5 H), 3.84 (s, 3 H), 2.85 (t, J = 6.4 Hz, 2 H), 2.62 (t, J = 6.5 Hz, 2 H), 1.78–1.58 (m, 4 H); ^{13}C NMR (50 MHz, CDCl$_3$): δ 194.0, 161.4, 141.8, 128.3, 128.1, 125.8, 52.9, 39.1, 35.5, 30.6, 22.5; MS (m/z, ESI): [M + NH$_4$]$^+$ calcd. for $C_{13}H_{16}O_3$ 238.1, found, 238.2; HRMS (m/z, ESI): [M + Na]$^+$ calcd. for $C_{13}H_{16}O_3$, 243.0992; found, 243.0994; analysis (calcd., found for $C_{13}H_{16}O_3$): C (70.89, 70.58), H (7.32, 7.46).

Methyl 6-(naphthalen-2-yl)-2-oxohexanoate (10b, GK451).   Yield 73%; Colorless oil; ^{1}H NMR (200 MHz, CDCl$_3$): δ 7.90–7.10 (m, 7 H), 3.85 (s, 3 H), 2.92–2.71 (m, 4 H), 1.83–1.49 (m, 4 H); ^{13}C NMR (50 MHz, CDCl$_3$): δ 194.0, 161.4, 139.2, 133.5, 131.9, 127.9, 127.5, 127.4, 127.2, 126.3, 125.9, 125.1, 52.9, 39.1, 35.6, 30.4, 22.5; MS (m/z, ESI): [(M + NH$_4$)$^+$] calcd. for $C_{17}H_{18}O_3$ 288.2, found, 288.2; HRMS (m/z, ESI): [M + Na]$^+$ calcd. for $C_{17}H_{18}O_3$, 293.1148; found, m/z 293.1149; analysis (calcd., found for $C_{17}H_{18}O_3$): C (75.53, 75.32), H (6.71, 6.95).

Methyl 2-oxohexadecanoate (10e).   Yield 73%; White solid; mp: 53–55 °C; ^{1}H NMR (200 MHz, CDCl$_3$): δ 3.85 (s, 3 H), 2.82 (t, J = 7.2 Hz, 2 H), 1.70–1.51 (m, 2 H), 1.37–1.16 (m, 22 H), 0.86 (t, J = 7.0 Hz, 3 H); ^{13}C NMR (50 MHz, CDCl$_3$): δ 194.3, 161.5, 52.8, 39.3, 31.9, 29.6, 29.5, 29.4, 29.3, 29.2, 28.9, 22.9, 22.6, 14.1; MS (m/z, ESI): [M + NH$_4$]$^+$ calcd. for $C_{17}H_{32}O_3$ 302.3; found, 302.3[61].

4-(tert-Butoxy)-4-oxobutyl 2-oxohexadecanoate (16a).   Yield 87%; Colorless oil, ^{1}H NMR (200 MHz, CDCl$_3$): δ 4.27 (t, J = 6.0 Hz, 2 H), 2.81 (t, J = 7.8 Hz, 2 H), 2.33 (t, J = 6.0 Hz, 2 H), 2.04 (quint, J = 6.0 Hz, 2 H), 1.70–1.50 (m, 2 H), 1.44 (s, 9 H), 1.40–1.15 (m, 22 H), 0.86 (t, J = 7.0 Hz, 3 H); ^{13}C NMR (50 MHz, CDCl$_3$): δ 194.5, 171.8, 161.2, 80.6, 65.2, 39.3, 31.9, 31.6, 29.6, 29.5, 29.4, 29.3, 29.2, 28.9, 28.0, 23.8, 22.9, 22.6, 14.1; MS (m/z, ESI): [M + NH$_4$]$^+$ calcd. for $C_{24}H_{44}O_5$ 430.4; found, 430.4; analysis (calcd., found for $C_{24}H_{44}O_5$): C (69.86, 69.6), H (10.75, 10.92).

Compound **16b** was not isolated and used directly in the next step.

4-(tert-Butoxy)-4-oxobutyl 2-oxo-6-phenylhexanoate (16c, GK192).   Yield 77%; Yellow oil; ^{1}H NMR (200 MHz, CDCl$_3$): δ 7.35–7.10 (m, 5 H), 4.26 (t, J = 8.0 Hz, 2 H), 2.84 (t, J = 6.0 Hz, 2 H), 2.70–2.55 (m, 2 H), 2.32 (t, J = 6.0 Hz, 2 H), 2.00 (quint, J = 6.0 Hz, 2 H), 1.70–1.60 (m, 4 H), 1.44 (s, 9 H); ^{13}C NMR (50 MHz, CDCl$_3$): δ 194.1, 171.7, 161.1, 141.8, 128.3, 128.2, 125.8, 80.6, 65.3, 39.1, 35.5, 31.6, 30.6, 28.0, 23.8, 22.5; HRMS (m/z, ESI): [M + Na]$^+$ calcd. for $C_{20}H_{28}O_5$ 371.1829; found, 371.1831; analysis (calcd., found for $C_{20}H_{28}O_5$): C (68.94, 68.66), H (8.10, 8.29).

4-tert-Butoxy-4-oxobutyl 6-(biphenyl-4-yl)-2-oxohexanoate (16d).   Yield 86%; Colorless oil; ^{1}H NMR (200 MHz, CDCl$_3$): δ 7.96–7.16 (m, 9 H), 4.28 (t, J = 6.4 Hz, 2 H), 2.97–2.83 (m, 2 H), 2.77–2.62 (m, 2 H), 2.42–2.28 (m, 2 H), 2.11–1.55 (m, 6 H), 1.45 (s, 9 H); ^{13}C NMR (50 MHz, CDCl$_3$): δ 194.1, 171.8, 161.0, 140.9, 138.7, 129.0, 128.9, 128.7, 128.6, 127.2, 127.0, 126.9, 80.6, 65.3, 39.1, 35.1, 31.6, 30.5, 28.0, 23.7, 22.5; MS (m/z, ESI): [M + Na]$^+$ calcd. for $C_{26}H_{32}O_5$ 447.2; found, 447.0; analysis (calcd., found for $C_{26}H_{32}O_5$): C (73.56, 73.35), H (7.60, 7.78).

5-(tert-Butoxy)-5-oxopentyl 2-oxohexadecanoate (16e).   Yield 78%; White oil; ^{1}H NMR (200 MHz, CDCl$_3$): δ 4.23 (t, J = 6.9 Hz, 2 H), 2.79 (t, J = 7.3 Hz, 2 H), 2.24 (t, J = 6.9 Hz, 2 H), 1.80–1.45 (m, 4 H), 1.44 (s, 9 H), 1.30–1.15 (s, 24 H), 0.85 (t, J = 7.0 Hz, 3 H); ^{13}C NMR (50 MHz, CDCl$_3$): δ 194.8, 172.6, 161.5, 80.5, 66.0, 39.5, 35.0, 32.1, 29.9, 29.8, 29.6, 29.5, 29.1, 28.3, 27.9, 23.1, 22.9, 21.6, 14.3; MS (m/z, ESI): [M + NH$_4$]$^+$ calcd. for $C_{25}H_{46}O_5$ 444.4; found, 444.3; analysis (calcd., found for $C_{25}H_{46}O_5$): C (70.38, 70.17), H (10.87, 11.05).

5-(tert-Butoxy)-5-oxopentyl 6-([1,1′-biphenyl]-4-yl)-2-oxohexanoate (16f).   Yield 63%; Colorless oil; ^{1}H NMR (200 MHz, CDCl$_3$): δ 7.66–7.19 (m, 9 H), 4.25 (t, J = 6.0 Hz, 2 H), 2.87 (t, J = 6.3 Hz, 2 H), 2.68 (t,

J = 6.1 Hz, 2 H), 2.26 (t, J = 7.0 Hz, 2 H), 1.86–1.53 (m, 8 H), 1.44 (s, 9 H); ^{13}C NMR (50 MHz, CDCl$_3$): δ 194.3, 172.4, 161.1, 141.0, 138.8, 129.0, 128.8, 128.7, 127.2, 127.0, 126.9, 80.3, 65.9, 39.1, 35.2, 34.8, 30.6, 28.1, 27.7, 22.5, 21.3; MS (m/z, ESI): [M + NH$_4$]$^+$ calcd. for C$_{27}$H$_{34}$O$_5$ 456.3; found, 456.3; analysis (calcd., found for C$_{27}$H$_{34}$O$_5$): C (73.95, 73.75), H (7.81, 7.99).

4-(*tert*-Butoxy)-4-oxobutyl 5-([1,1′-biphenyl]-4-yl)-2-oxopentanoate (16 g). Yield 65%;
Colorless oil; ^{1}H NMR (200 MHz, CDCl$_3$): δ 7.64–7.20 (m, 9 H), 4.27 (t, J = 6.4 Hz, 2 H), 2.88 (t, J = 7.2 Hz, 2 H), 2.70 (t, J = 7.5 Hz, 2 H), 2.33 (t, J = 7.2 Hz, 2 H), 2.10–1.90 (m, 4 H), 1.44 (s, 9 H); ^{13}C NMR (50 MHz, CDCl$_3$): δ 194.3, 172.1, 161.3, 141.2, 140.5, 139.3, 129.1, 128.9, 127.4, 127.3, 127.2, 80.9, 65.6, 38.8, 34.6, 31.9, 28.3, 24.7, 24.0; MS (m/z, ESI): [M + NH$_4$]$^+$ calcd. for C$_{25}$H$_{30}$O$_5$ 428.2; found, 428.3; analysis (calcd., found for C$_{25}$H$_{30}$O$_5$): C (73.15, 72.97), H (7.37, 7.56).

5-(*tert*-Butoxy)-5-oxopentyl 5-([1,1′-biphenyl]-4-yl)-2-oxopentanoate (16 h). Yield 61%;
Colorless oil; ^{1}H NMR (200 MHz, CDCl$_3$): δ 7.64–7.20 (m, 9 H), 4.24 (t, J = 6.0 Hz, 2 H), 2.87 (t, J = 6.3 Hz, 2 H), 2.69 (t, J = 7.5 Hz, 2 H), 2.25 (t, J = 5.9 Hz, 2 H), 2.20–1.90 (m, 2 H), 1.90–1.54 (m, 4 H), 1.44 (s, 9 H); ^{13}C NMR (50 MHz, CDCl$_3$); δ 194.4, 172.7, 161.3, 141.2, 140.5, 139.3, 129.1, 128.9, 127.4, 127.3, 127.2, 80.6, 66.2, 38.8, 35.1, 34.6, 28.3, 27.9, 24.7, 21.6; MS (m/z, ESI): [M + NH$_4$]$^+$ calcd. for C$_{26}$H$_{32}$O$_5$ 442.3; found, 442.3; analysis (calcd., found for C$_{26}$H$_{32}$O$_5$): C (73.56, 73.32), H (7.60, 7.82).

4-Ethoxy-4-oxobutyl 2-oxo-6-phenylhexanoate (19, GK194). Yield 73%; Yellowish oil, ^{1}H NMR
(200 MHz, CDCl$_3$): δ 7.30–7.10 (m, 5 H), 4.28 (t, J = 8.0 Hz, 2 H), 4.13 (q, J = 6.0 Hz, 2 H) 2.84 (t, J = 6.0 Hz, 2 H), 2.70–2.55 (m, 2 H), 2.41 (t, J = 8.0 Hz, 2 H), 2.15–1.95 (m, 2 H), 1.70–1.55 (m, 4 H), 1.24 (t, J = 6.0 Hz, 3 H); ^{13}C NMR (50 MHz, CDCl$_3$): δ 194.0, 172.4, 161.0, 141.8, 128.3, 128.2, 125.7, 65.2, 60.5, 39.0, 35.5, 30.6, 30.5, 23.6, 22.5, 14.1; MS (m/z, ESI): [M + NH$_4$]$^+$calcd. for C$_{18}$H$_{24}$O$_5$ 338.2; found, 338.2;HRMS (m/z, ESI): [M + Na]$^+$ calcd for C$_{18}$H$_{24}$O$_5$ 343.1516; found, 343.1512; analysis (calcd., found for C$_{18}$H$_{24}$O$_5$): C (67.48, 67.19), H (7.55, 7.61).

Synthesis of 2-hydroxy acids 11α-e. To a stirred solution of 2-hydroxy ester 9a-e (1 mmol) in methanol
(10 mL), aqueous NaOH (1.1 mL, 1 N) was added and the reaction mixture was stirred overnight at room temperature. The organic solvent was evaporated *in vacuo* to dryness and then aqueous HCl 1 N was added until acidic pH. The aqueous phase was washed with EtOAc (3 × 10 mL). Finally, the organic phase was dried (Na$_2$SO$_4$) and evaporated under reduced pressure.

6-([1,1′-Biphenyl]-4-yl)-2-hydroxyhexanoic acid (11c). Yield 99%; White solid; mp: 143–145 °C; ^{1}H
NMR (200 MHz, CDCl$_3$): δ 10.43 (s, 1 H), 7.67–7.02 (m, 9 H), 5.00 (br s, 1 H) 4.22 (t, J = 6.0 Hz, 1 H), 2.59 (t, J = 7.2 Hz, 2 H), 2.03–1.37 (m, 6 H); ^{13}C NMR (50 MHz, CDCl$_3$): δ 176.6, 141.2, 140.6, 138.1, 129.1, 128.3, 128.2, 126.5, 126.4, 69.8, 34.9, 33.6, 30.8, 24.3; MS (m/z, ESI): [M-H]$^-$ calcd. for C$_{18}$H$_{20}$O$_3$ 283.1; found, 283.1; analysis (calcd., found for C$_{18}$H$_{20}$O$_3$): C (76.03, 75.85), H (7.09, 7.25).

5-([1,1′-Biphenyl]-4-yl)-2-hydroxypentanoic acid (11d). Yield 64% (over two steps); Light violet vis-
cous oil; ^{1}H NMR (200 MHz, CDCl$_3$): δ 10.60 (s, 1 H), 7.66–7.06 (m, 9 H), 4.98 (s, 1 H), 4.29 (t, J = 6.0 Hz, 1 H), 2.68 (t, J = 6.4 Hz, 2 H), 1.99–1.68 (m, 4 H); ^{13}C NMR (50 MHz, CDCl$_3$): δ 178.4, 141.3, 141.2, 139.0, 129.1, 129.0, 128.9, 127.3, 127.2, 70.3, 35.3, 33.9, 26.8; MS (m/z, ESI): [M-H]$^-$ calcd. for C$_{17}$H$_{18}$O$_3$ 269.1; found, 269.1; analysis (calcd., found for C$_{17}$H$_{18}$O$_3$): C (75.53, 75.31), H (6.71, 6.87).

2-Oxohexadecanoic acid (12e). To a stirred solution of 9e (0.35 mmol, 100 mg) in MeOH (3.5 mL), aque-
ous Cs$_2$CO$_3$ 20% (w/v) (1.7 mL, 1.0 mmol) was added, and the reaction mixture was stirred at room temperature. The reaction progress was monitored by TLC, until completion. The organic solvent was evaporated *in vacuo* to dryness, water was added (10 mL) and then aqueous HCl 1 N was added until acidic pH. The aqueous phase was washed with EtOAc (3 × 10 mL). Finally, the organic phase was dried over Na$_2$SO$_4$ and evaporated under reduced pressure. Yield 32%; White solid; mp: 66–68 °C; ^{1}H NMR (200 MHz, CDCl$_3$): δ 9.02 (br s, 1 H), 2.93 (t, J = 7.2 Hz, 2 H), 1.76–1.51 (m, 2 H), 1.43–1.05 (m, 22 H), 0.88 (t, J = 6.6 Hz, 3 H); ^{13}C NMR (50 MHz, CDCl$_3$): δ 194.8, 162.5, 39.3, 31.9, 29.6, 29.5, 29.4, 29.3, 29.2, 28.9, 22.9, 22.7, 14.1; MS (m/z, ESI): [M-H]$^-$ calcd. for C$_{16}$H$_{30}$O$_3$ 269.2; found, 269.2[62].

Synthesis of 2-hydroxy esters 15a-h and 18. To a stirred solution of 2-hydroxy acids 11a, 11c, 11d,
13a,b (1 mmol) in tetrahydrofuran (THF) (6 mL), water (0.6 mL) and few drops of aqueous CsCO$_3$ 20% (w/v) were added in order to adjust pH in neutral value. The organic solvent was evaporated *in vacuo* and the residue was dissolved in N,N-dimethylformamide (DMF) (15 mL). Subsequently, *tert*-butyl 5-bromoalkanooate 14a,b or ethyl 4-bromobutyrate (1.2 mmol) was added and the reaction mixture was refluxed for 72 h. Water (20 mL) was then added and the reaction mixture was washed with EtOAc (2 × 20 mL). The organic phase was dried (Na$_2$SO$_4$) and evaporated under reduced pressure. The residue was purified by flash column chromatography [EtOAc-petroleum ether (bp 40–60 °C), 1:9 or 2:8].

4-(*tert*-Butoxy)-4-oxobutyl 2-hydroxyhexadecanoate (15a). Yield 44%; Yellow oil, ^{1}H NMR
(200 MHz, CDCl$_3$): δ 4.25–4.10 (m, 3 H), 2.73 (br s, 1 H), 2.30 (t, J = 6.0 Hz, 2 H), 1.94 (qu, J = 6.0 Hz, 2 H), 1.60–1.45 (m, 2 H), 1.43 (s, 9 H), 1.40–1.20 (m, 24 H), 0.86 (t, J = 6.0 Hz, 3 H); ^{13}C NMR (50 MHz, CDCl$_3$): δ 175.3, 171.9, 80.6, 70.4, 64.5, 34.4, 31.9, 31.7, 29.6, 29.5, 29.4, 29.3, 28.0, 24.7, 24.0, 22.6, 14.1; MS (m/z, ESI): [M + NH$_4$]$^+$ cald. for C$_{24}$H$_{46}$O$_5$ 432.4; found, 432.3; analysis (calcd., found for C$_{24}$H$_{46}$O$_5$): C (69.52, 69.36), H (11.18, 11.29).

4-(*tert*-Butoxy)-4-oxobutyl 6-(4-(hexyloxy)phenyl)-2-hydroxyhexanoate (15b). Yield 35%; Yellowish oil, ^{1}H NMR (200 MHz, CDCl$_3$): δ 7.08 (d, J = 8.6 Hz, 2 H), 6.82 (d, J = 8.6 Hz, 2 H), 4.27–4.12 (m, 3 H), 3.93 (t, J = 6.0 Hz, 2 H), 2.78 (br s, 1 H), 2.58 (t, J = 7.0 Hz, 2 H), 2. 30 (t, J = 7.0 Hz, 2 H), 1.95 (q, J = 7.0 Hz, 2 H), 1.85–1.47 (m, 8 H), 1.46 (s, 9 H) 1.45–1.20 (m, 6 H), 0.91 (t, J = 7.0 Hz, 3 H); ^{13}C NMR (50 MHz, CDCl$_3$): δ 175.1, 172.8, 157.1, 134.1, 129.1, 114.2, 80.3, 70.3, 67.9, 64.4, 34.7, 34.2, 31.5, 31.3, 30.3, 29.2, 28.0, 25.7, 24.4, 23.6, 22.5, 14.0; MS (m/z, ESI): [M + NH$_4$]$^+$ calcd. for C$_{26}$H$_{42}$O$_6$ 468.3; found, 468.1; analysis (calcd., found for C$_{26}$H$_{42}$O$_6$): C (69.30, 69.08), H (9.40, 9.61).

4-(*tert*-Butoxy)-4-oxobutyl 2-hydroxy-6-phenylhexanoate (15c). Yield 50%; Yellow oil, ^{1}H NMR (200 MHz, CDCl$_3$): δ 7.33–7.08 (m, 5 H), 4.23–4.10 (m, 3 H), 2.86 (br s, 1 H), 2.61 (t, J = 7.0 Hz, 2 H), 2.28 (t, J = 7.0 Hz, 2 H), 2.00–1.75 (m, 2 H), 1.70–1.45 (m, 6 H), 1.44 (s, 9 H); ^{13}C NMR (50 MHz, CDCl$_3$): δ 175.1, 162.8, 142.3, 128.3, 128.1, 125.6, 80.3, 70.3, 64.5, 36.5, 35.7, 34.2, 31.5, 28.0, 24.4, 23.9; MS (m/z, ESI): [M + NH$_4$]$^+$ calcd. for C$_{20}$H$_{30}$O$_5$ 368.2; found, 368.3; analysis (calcd., found for C$_{20}$H$_{30}$O$_5$): C (68.55, 68.34), H (8.63, 8.81).

4-*tert*-Butoxy-4-oxobutyl 6-(biphenyl-4-yl)-2-hydroxyhexanoate (15d). Yield 61%; Oil, ^{1}H NMR (200 MHz, CDCl$_3$): δ 7.64–7.19 (m, 9 H), 4.41–4.00 (m, 3 H), 2.75 (br s, 1 H), 2.67 (t, J = 7.4 Hz, 2 H), 2.30 (t, J = 7.4 Hz, 2 H), 2.03–1.48 (m, 8 H), 1.45 (s, 9 H); ^{13}C NMR (50 MHz, CDCl$_3$): δ 175.1, 171.8, 141.4, 138.5, 129.5, 128.7, 128.6, 126.9, 126.8, 80.5, 70.2, 64.5, 35.3, 34.2, 31.6, 31.1, 28.0, 24.4, 23.9; MS (m/z, ESI): [M + Na]$^+$ calcd. for C$_{26}$H$_{34}$O$_5$ 449.2; found, 449.2; analysis (calcd., found for C$_{26}$H$_{34}$O$_5$): C (73.21, 73.00), H (8.03, 8.21).

5-(*tert*-Butoxy)-5-oxopentyl 2-hydroxyhexadecanoate (15e). Yield 48%; Light yellow oil; ^{1}H NMR (200 MHz, CDCl$_3$): δ 4.19–4.05 (m, 3 H), 2.84 (br s, 1 H), 2.21 (t, J = 6.7 Hz, 2 H), 1.70–1.45 (m, 8 H), 1.40 (s, 9 H), 1.30–1.15 (m, 22 H), 0.83 (t, J = 6.3 Hz, 3 H); ^{13}C NMR (50 MHz, CDCl$_3$): δ 175.6, 172.7, 80.5, 70.7, 65.3, 35.0, 34.6, 32.1, 29.9, 29.8, 29.7, 29.6, 29.5, 28.2, 28.1, 25.0, 22.9, 21.6, 14.3; MS (m/z, ESI): [M + NH$_4$]$^+$ calcd. for C$_{25}$H$_{48}$O$_5$ 446.4; found, 446.3; analysis (calcd., found for C$_{25}$H$_{48}$O$_5$): C (70.05, 69.89), H (11.29, 11.44).

5-(*tert*-Butoxy)-5-oxopentyl 6-([1,1′-biphenyl]-4-yl)-2-hydroxyhexanoate (15f). Yield 70%; Colorless oil; ^{1}H NMR (200 MHz, CDCl$_3$): δ 7.64–7.14 (m, 9 H), 4.24–4.03 (m, 3 H), 2.70–2.54 (m, 3 H), 2.24 (t, J = 6.6 Hz, 2 H), 1.86–1.53 (m, 10 H), 1.44 (s, 9 H); ^{13}C NMR (50 MHz, CDCl$_3$): δ 175.3, 172.5, 141.5, 138.6, 129.5, 128.8, 128.7, 127.0, 126.9, 80.3, 70.3, 65.2, 35.4, 34.8, 34.3, 31.1, 28.1, 27.9, 24.5, 21.4; MS (m/z, ESI): [M + NH$_4$]$^+$ calcd. for C$_{27}$H$_{36}$O$_5$ 458.3; found, 458.2; analysis (calcd., found for C$_{27}$H$_{36}$O$_5$): C (73.61, 73.37), H (8.24, 8.39).

4-(*tert*-Butoxy)-4-oxobutyl 5-([1,1′-biphenyl]-4-yl)-2-hydroxypentanoate (15g). Yield 26%; Colorless oil; ^{1}H NMR (200 MHz, CDCl$_3$): δ 7.64–7.20 (m, 9 H), 4.21 (m, 3 H), 2.85 (br s, 1 H), 2.69 (t, J = 7.0 Hz, 2 H), 2.29 (t, J = 7.2 Hz, 2 H), 2.06–1.66 (m, 6 H), 1.45 (s, 9 H); ^{13}C NMR (50 MHz, CDCl$_3$): δ 175.2, 172.6, 141.1, 139.2, 129.5, 128.8, 127.3, 127.2, 127.0, 80.8, 69.9, 64.8, 35.9, 34.8, 34.4, 28.4, 26.7, 21.5; MS (m/z, ESI): [M + NH$_4$]$^+$ calcd. for C$_{25}$H$_{32}$O$_5$ 430.3; found, 430.3; analysis (calcd., found for C$_{25}$H$_{32}$O$_5$): C (72.79, 72.60), H (7.82, 7.92).

5-(*tert*-Butoxy)-5-oxopentyl 5-([1,1′-biphenyl]-4-yl)-2-hydroxypentanoate (15h). Yield 54%; Colorless oil; ^{1}H NMR (200 MHz, CDCl$_3$): δ 7.64–7.18 (m, 9 H), 4.30–4.08 (m, 3 H), 2.87 (br s, 1 H), 2.68 (t, J = 6.0 Hz, 2 H), 2.23 (t, J = 5.9 Hz, 2 H), 1.90–1.50 (m, 8 H), 1.44 (s, 9 H); ^{13}C NMR (50 MHz, CDCl$_3$): δ 175.5, 172.8, 141.3, 139.0, 129.0, 128.9, 127.3, 127.2, 127.1, 80.6, 70.5, 65.5, 35.3, 35.1, 34.2, 28.3, 28.1, 26.8, 21.7; MS (m/z, ESI): [M + NH$_4$]$^+$ calcd. for C$_{26}$H$_{34}$O$_5$ 444.3; found, 444.3; analysis (calcd., found for C$_{26}$H$_{34}$O$_5$): C (73.21, 73.07), H (8.03, 8.19).

4-Ethoxy-4-oxobutyl 2-hydroxy-6-phenylhexanoate (18). Yield 57%; Yellow oil, ^{1}H NMR (200 MHz, CDCl$_3$): δ 7.30–7.05 (m, 5 H), 4.24–4.00 (m, 5 H), 2.92 (br s, 1 H), 2.61 (t, J = 7.1 Hz, 2 H), 2.36 (t, J = 6.0 Hz, 2 H), 1.96 (t, J = 7.1 Hz, 2 H), 1.80–1.60 (m, 4 H), 1.60–1.40 (m, 2 H), 1.24 (t, J = 6.0 Hz, 3 H); ^{13}C NMR (50 MHz, CDCl$_3$): δ 175.1, 172.5, 142.2, 128.2, 128.1, 125.6, 70.2, 64.4, 60.5, 35.6, 34.1, 31.0, 30.5, 24.4, 23.8, 14.1; MS (m/z, ESI): [M + NH$_4$]$^+$ calcd. for C$_{18}$H$_{26}$O$_5$ 340.2; found, 340.3; analysis (calcd., found for C$_{18}$H$_{26}$O$_5$): C (67.06, 66.93), H (8.13, 8.28).

Synthesis of compounds 17a-h and 20. A solution of *tert*-butyl ester **16a-h** and **15a** (1 mmol) in 50% trifluoroacetic acid (TFA) in CH$_2$Cl$_2$ (10 mL) was stirred for 1 h at room temperature. The organic solvent was evaporated under reduced pressure and then CH$_2$Cl$_2$ was added and re-evaporated twice. The product was purified by precipitation with a mixture of EtOAc and petroleum ether (5:95, v/v, 10 mL) or by column chromatography (CH$_2$Cl$_2$-MeOH, 95:5).

4-((2-Oxohexadecanoyl)oxy)butanoic acid (17a, GK161). Yield 85%; White solid; mp: 76–78 °C; ^{1}H NMR (200 MHz, CDCl$_3$): δ 9.25 (br s, 1 H), 4.32 (t, J = 6.0 Hz, 2 H), 2.82 (t, J = 6.0 Hz, 2 H), 2.51 (t, J = 6.0 Hz, 2 H), 2.15 (q, J = 6.0 Hz, 2 H), 1.80–1.50 (m, 2 H), 1.50–1.20 (m, 22 H), 0.88 (t, J = 7.0 Hz, 3 H); ^{13}C NMR (50 MHz, CDCl$_3$): δ 194.3, 178.6, 161.1, 65.0, 39.3, 31.9, 30.3, 29.6, 29.6, 29.4, 29.3, 29.3, 28.9, 23.4, 22.9, 22.7, 14.1; HRMS (m/z, ESI): [M-H]$^-$ calcd. for C$_{20}$H$_{36}$O$_5$ 355.2490; found, 355.2487; analysis (calcd., found for C$_{20}$H$_{36}$O$_5$): C (67.38, 67.12), H (10.18, 10.39).

4-((6-(4-(Hexyloxy)phenyl)-2-oxohexanoyl)oxy)butanoic acid (17b, GK186). Yield 54%; Low melting point white solid; ^{1}H NMR (200 MHz, CDCl$_3$): δ 9.20 (br s, 1 H), 7.04 (d, J = 8.6 Hz, 2 H), 6.77 (d, J = 8.6 Hz, 2 H), 4.26 (t, J = 7.0 Hz, 2 H), 3.89 (t, J = 7.0 Hz, 2 H), 2.81 (t, J = 7.0 Hz, 2 H), 2.60–2.45 (m, 2 H), 2.39 (t, J = 7.0 Hz, 2 H), 2.00 (q, J = 7.0 Hz, 2 H), 1.72 (t, J = 7.0 Hz, 2 H), 1.65–1.50 (m, 4 H), 1.48–1.35 (m, 2 H),

1.35–1.20 (m, 4 H), 0.86 (t, J = 7.0 Hz, 3 H); ^{13}C NMR (50 MHz, CDCl$_3$): δ 194.4, 178.1, 161.8, 157.1, 134.1, 129.1, 114.2, 67.9, 65.4, 34.7, 34.2, 31.5, 30.3, 29.2, 28.0, 25.7, 24.4, 23.6, 22.5, 14.0; MS (m/z, ESI): [M-H]$^-$ calcd. for C$_{22}$H$_{32}$O$_6$ 391.2; found, 391.4; HRMS (m/z, ESI): [M-H]$^-$ calcd. for C$_{22}$H$_{32}$O$_6$ 391.2126; found, 391.2122; analysis (calcd., found for C$_{22}$H$_{32}$O$_6$): C (67.32, 67.13), H (8.22, 8.39).

4-((2-Oxo-6-phenylhexanoyl)oxy)butanoic acid (17c). Yield 60%; Colorless oil; ^{1}H NMR (200 MHz, CDCl$_3$): δ 9.23 (br s, 1 H), 7.32–7.05 (m, 5 H), 4.29 (t, J = 6.0 Hz, 2 H), 2.84 (t, J = 8.0 Hz, 2 H), 2.63 (t, J = 8.0 Hz, 2 H), 2.48 (t, J = 6.0 Hz, 2 H), 2.06 (q, J = 8.0 Hz, 2 H), 1.75–1.55 (m, 4 H); ^{13}C NMR (50 MHz, CDCl$_3$): δ 194.3, 178.9, 161.3, 142.1, 128.6, 128.1, 126.1, 65.3, 39.3, 35.8, 30.8, 30.5, 23.6, 22.7; MS (m/z, ESI): [M + NH$_4$]$^+$ calcd. for C$_{16}$H$_{20}$O$_5$ 310.2; found, 310.1; analysis (calcd., found for C$_{16}$H$_{20}$O$_5$): C (65.74, 65.53), H (6.90, 7.08).

4-(6-(Biphenyl-4-yl)-2-oxohexanoyloxy)butanoic acid (17d, GK200). Yield 94%; White solid; mp: 101–103 °C; ^{1}H NMR (200 MHz, CDCl$_3$): δ 9.25 (br s, 1 H),7.63–7.17 (m, 9 H), 4.37–4.21 (m, 2 H), 2.93–2.79 (m, 2 H), 2.75–2.58 (m, 2 H), 2.55–2.40 (m, 2 H), 2.14–1.95 (m, 2 H), 1.81–1.59 (m, 4 H); ^{13}C NMR (50 MHz, CDCl$_3$): δ 194.0, 178.7, 160.9, 141.0, 140.2, 138.7, 128.8, 128.7, 127.2, 127.0, 126.9, 65.0, 39.1, 35.1, 30.5, 30.2, 23.3, 22.5; MS (m/z, ESI): [M-H]$^-$ calcd. for C$_{22}$H$_{24}$O$_5$ 367.2; found, 367.3; HRMS (m/z, ESI): [M-H]$^-$ calcd. for C$_{22}$H$_{24}$O$_5$ 367.1551; found, 367.1544; analysis (calcd., found for C$_{22}$H$_{24}$O$_5$): C (71.72, 71.49), H (6.57, 6.79).

5-((2-Oxohexadecanoyl)oxy)pentanoic acid (17e, GK433). Yield 66%; White solid; mp: 77–79 °C; ^{1}H NMR (200 MHz, CDCl$_3$): δ 9.28 (br s, 1 H), 4.25 (t, J = 6.0 Hz, 2 H), 2.80 (t, J = 7.3 Hz, 2 H), 2.40 (t, J = 6.8 Hz, 2 H), 1.88–1.46 (m, 6 H), 1.34–1.15 (m, 22 H), 0.85 (t, J = 7.0 Hz, 3 H); ^{13}C NMR (50 MHz, CDCl$_3$): δ 194.8, 179.6, 161.4, 65.9, 39.6, 33.6, 32.1, 29.9, 29.8, 29.7, 29.6, 29.5, 29.2, 27.9, 23.2, 22.9, 21.2, 14.4; HRMS (m/z, ESI): [M-H]$^-$ calcd. for C$_{21}$H$_{38}$O$_5$ 369.2646; found, 369.2660; analysis (calcd., found for C$_{21}$H$_{38}$O$_5$): C (68.07, 67.82), H (10.34, 10.52).

5-((6-([1,1′-Biphenyl]-4-yl)-2-oxohexanoyl)oxy)pentanoic acid (17f, GK452). Yield 91%; White solid; mp: 83–85 °C; ^{1}H NMR (200 MHz, CDCl$_3$): δ 9.25 (bs, 1 H), 7.64–7.12 (m, 9 H), 4.25 (t, J = 7.0 Hz, 2 H), 2.87 (t, J = 6.0 Hz, 2 H), 2.67 (t, J = 5.9 Hz, 2 H), 2.40 (t, J = 6.3 Hz, 2 H), 1.89–1.54 (m, 8 H); ^{13}C NMR (50 MHz, CDCl$_3$): δ 194.2, 179.0, 161.1, 141.0, 138.7, 128.8, 128.7, 127.0, 126.9, 65.7, 39.1, 35.2, 33.2, 30.6, 27.6, 22.5, 20.9; MS (m/z, ESI): [M + NH$_4$]$^+$ calcd. for C$_{23}$H$_{26}$O$_5$ 400.2; found, 400.2; HRMS (m/z, ESI): [M + Na]$^+$ calcd. for C$_{23}$H$_{26}$O$_5$ 405.1672; found, 405.1677; analysis (calcd., found for C$_{23}$H$_{26}$O$_5$): C (72.23, 72.04), H (6.85, 6.99).

4-((5-([1,1′-Biphenyl]-4-yl)-2-oxopentanoyl)oxy)butanoic acid (17g, GK457). Yield 47%; Light yellow solid; mp: 58–60 °C; ^{1}H NMR (200 MHz, CDCl$_3$): δ 10.06 (br s, 1 H), 7.66–7.18 (m, 9 H), 4.29 (t, J = 6.3 Hz, 2 H), 2.88 (t, J = 7.2 Hz, 2 H), 2.70 (t, J = 8.0 Hz, 2 H), 2.49 (t, J = 7.2 Hz, 2 H), 2.15–1.90 (m, 4 H); ^{13}C NMR (50 MHz, CDCl$_3$): δ 194.1, 178.2, 161.1, 141.2, 140.2, 139.3, 129.1, 128.9, 127.4, 127.3, 127.2, 65.3, 38.7, 34.5, 30.4, 24.6, 23.6; HRMS (m/z, ESI): [M + Na]$^+$ calcd. for C$_{21}$H$_{22}$O$_5$ 377.1359; found, 377.1357; analysis (calcd., found for C$_{21}$H$_{22}$O$_5$): C (71.17, 71.02), H (6.26, 6.45).

5-((5-([1,1′-Biphenyl]-4-yl)-2-oxopentanoyl)oxy)pentanoic acid (17h, GK458). Yield 65%; Light yellow solid; mp: 88–90 °C; ^{1}H NMR (200 MHz, CDCl$_3$): δ 9.81 (br s, 1 H), 7.65–7.18 (m, 9 H), 4.25 (t, J = 6.9 Hz, 2 H), 2.88 (t, J = 7.2 Hz, 2 H), 2.71 (t, J = 7.5 Hz, 2 H), 2.40 (t, J = 6.7 Hz, 2 H), 2.12–1.90 (m, 2 H), 1.81–1.65 (m, 4 H); ^{13}C NMR (50 MHz, CDCl$_3$): δ 194.4, 179.5, 161.3, 141.2, 140.5, 139.3, 129.1, 128.9, 127.4, 127.3, 127.2, 66.0, 38.8, 34.6, 33.6, 27.9, 24.7, 21.2. HRMS (m/z, ESI): [M + Na]$^+$ calcd. for C$_{22}$H$_{24}$O$_5$ 391.1516; found, 391.1504; analysis (calcd., found for C$_{22}$H$_{24}$O$_5$): C (71.72, 71.48), H (6.57, 6.71).

4-((2-Hydroxyhexadecanoyl)oxy)butanoic acid (20, GK515). Yield 85%; Low melting point white solid; ^{1}H NMR (200 MHz, CDCl$_3$): δ 9.26 (br s, 1 H), 4.30–4.10 (m, 3 H), 2.78 (br s, 1 H), 2.46 (t, J = 6.0 Hz, 2 H), 2.10–1.90 (m, 2 H), 1.85–1.50 (m, 4 H), 1.50–1.10 (m, 22 H), 0.87 (t, J = 7.0 Hz, 3 H); ^{13}C NMR (50 MHz, CDCl$_3$): δ 178.2, 175.4, 70.5, 64.4, 34.4, 31.9, 30.3, 29.7, 29.6, 29.5, 29.3, 24.8, 23.7, 22.7, 14.1; HRMS (m/z, ESI): [M-H]$^-$ calcd. for C$_{20}$H$_{38}$O$_5$ 357.2646; found, 357.2639; analysis (calcd., found for C$_{20}$H$_{38}$O$_5$): C (67.00, 66.81), H (10.68, 10.89).

***In vitro* PLA$_2$ activity assay.** The activities of human GVIA iPLA$_2$, GIV cPLA$_2$ and GV sPLA$_2$ were determine using a group-specific mixed micelle modified Dole assay[27, 28, 30]. The substrate was prepared using slightly different conditions for each enzyme to achieve optimum activity: (i) GIVA cPLA$_2$ mixed micelle substrate consisted of 400 μM Triton X-100, 95.3 μM PAPC, 1.7 μM arachidonyl-1-^{14}C PAPC, and 3 μM phosphatidyl inositol (4,5)-bisphosphate (PIP$_2$) in a buffer containing 100 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH 7.5, 90 μM CaCl$_2$, 2 mM dithiothreitol (DTT), and 0.1 mg/ml bovine serum albumin (BSA); (ii) GVIA iPLA$_2$ mixed micelle substrate consisted of 400 μM Triton X-100, 98.3 μM 1-palmitoyl-2-arachidonylphosphatidylcholine (PAPC), and 1.7 μM arachidonyl-1-^{14}C PAPC in a buffer containing 100 mM HEPES pH 7.5, 2 mM adenosine triphosphate (ATP), and 4 mM DTT; and (iii) GV sPLA$_2$ mixed micelles substrate consisted of 400 μM Triton X-100, 98.3 μM PAPC, and 1.7 μM arachidonyl-1-^{14}C PAPC in a buffer containing 50 mM tris(hydroxymethyl)aminomethane hydrochloride (Tris-HCl) pH 8.0, and 5 mM CaCl$_2$. The compounds were initially screened at 0.091 mole fraction (5 μL of 5 mM inhibitor in dimethyl sulfoxide (DMSO)) in substrate (495 μL). $X_I(50)$ was determined for compounds exhibiting greater than 95% inhibition. Inhibition curves were generated using GraphPad Prism 5.0 and the non-linear regression by plotting percentage of inhibition vs log (mole fraction) to calculate the reported $X_I(50)$ and its associated error.

Docking Calculations. Enzyme structures were optimized using the PPW. The structures of the inhibitors were sketched using Maestro sketcher and they were optimized using LigPrep. Glide was used for the rigid-docking of the compounds into the enzyme active site. The grid required for the docking procedure was generated using a scaling factor of 1.0 and partial charge cutoff of 0.25, while X, Y, Z dimensions of the inner box were set to 12 Å. For the inhibitor docking a scaling factor of 0.8 and partial charge cutoff of 0.15 were used that allow complete flexibility of the structures. The poses were selected according to the binding mode and the XP GScore. The Glide Extra-Precision (XP) scoring function was used for the calculations[63].

Macrophage Eicosanoid Production. RAW264.7 murine macrophage cells (ATCC #TIB-71) were maintained at 37 °C, 5% CO_2 in DMEM (Life Technologies 11995–065) containing 10% FBS (Gemini), 100 U/mL penicillin/streptomycin, 1 mM sodium pyruvate and 4 mM L-glutamine. Macrophages were plated in 12-well tissue culture plates in 1 mL phenol red-free DMEM (Life Technologies) at a concentration of 5×10^5 macrophages per well and were allowed to adhere for 24 hours. Wells receiving inhibitor treatment were spiked with **17f** to a final concentration of 5 μM and incubated for 1 hour at 37 °C. Kdo2-Lipid A (KLA; Avanti Polar Lipids) was then added to a final concentration of 100 ng/mL. Supernatants were collected at 24 hours for eicosanoid quantification. Cells were washed 2 times with 1 mL PBS and then collected in 1 mL PBS for determination of total protein concentration using a Pierce BCA assay kit (ThermoFisher). Supernatants and cellular material were stored at −80 °C until analysis. Supernatants were thawed on ice, and then spiked with 100 μL of an internal standard mix in ethanol (100 pg/μL; Cayman). Samples were purified via solid-phase extraction (SPE) and prepared for eicosanoid analysis as described in detail previously[64]. Briefly, following SPE, 10 μL of each sample was separated by reversed-phase liquid chromatography over 5.3 minutes using a gradient of the mobile phase A [water:acetonitrile:acetic acid (60:40:0.02; v/v/v)] and mobile phase B [acetonitrile:isopropanol (50:50; v/v)] on a 2.1×100 mm Acuity UPLC ® BEH Shield RP18 1.7 μm column. Online UPLC-electrospray ionization MS/MS quantitation of eicosanoids was performed on a QTRAP 6500 hybrid quadrupole/linear ion-trap mass spectrometer (AB Sciex) via multiple reaction monitoring (MRM) in negative ion mode. Eicosanoids were quantified by comparing the MRM signal and retention time to a pure standard. GraphPad Prism 7.0 was used for statistical analysis. Statistical significance was determined by one-way ANOVA analysis of variance and a Dunnett's post-test comparing all columns to KLA treatment, $P \leq 0.05$.

References

1. Dennis, E. A., Cao, J., Hsu, Y. H., Magrioti, V. & Kokotos, G. Phospholipase A_2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. *Chem. Rev.* **111**, 6130–6185 (2011).
2. Ghosh, M., Tucker, D. E., Burchett, S. A. & Leslie, C. C. Properties of the group IV phospholipase A_2 family. *Prog. Lipid Res.* **45**, 487–510 (2006).
3. Dennis, E. A. & Norris, P. C. Eicosanoid storm in infection and inflammation. *Nat. Rev. Immunol.* **15**, 511–523 (2015).
4. Murakami, M. *et al.* Recent progress in phospholipase A_2 research: from cells to animals to humans. *Prog. Lipid Res.* **50**, 152–192 (2011).
5. Leslie, C. C. Cytosolic phospholipase A_2: physiological function and role in disease. *J. Lipid Res.* **56**, 1386–1402 (2015).
6. Kirkby, N. S. *et al.* Inherited human group IVA cytosolic phospholipase A_2 deficiency abolishes platelet, endothelial, and leucocyte eicosanoid generation. *FASEB J.* **29**, 4568–4578 (2015).
7. Alonso, F., Henson, P. M. & Leslie, C. C. A cytosolic phospholipase in human neutrophils that hydrolyzes arachidonoyl-containing phosphatidylcholine. *Biochim. Biophys. Acta.* **878**, 273–280 (1986).
8. Kramer, R. M. *et al.* Solubilization and properties of Ca^{2+}-dependent human platelet phospholipase A_2. *Biochim. Biophys. Acta* **878**, 394–403 (1986).
9. Clark, J. D. *et al.* A novel arachidonic acid-selective cytosolic PLA_2 contains a Ca^{2+}-dependent translocation domain with homology to PKC and GAP. *Cell* **65**, 1043–1051 (1991).
10. Kramer, R. M., Roberts, E. F., Manetta, J. & Putnam, J. E. The Ca^{2+}-sensitive cytosolic phospholipase A_2 is a 100-kda protein in human monoblast U937 cells. *J. Biol. Chem.* **266**, 5268–5272 (1991).
11. Dessen, A. *et al.* Crystal structure of human cytosolic phospholipase A_2 reveals a novel topology and catalytic mechanism. *Cell* **97**, 349–360 (1999).
12. Sharp, J. D. *et al.* Serine 228 is essential for catalytic activities of 85-kDa cytosolic phospholipase A_2. *J. Biol. Chem.* **269**, 23250–23254 (1994).
13. Pickard, R. T. *et al.* Identification of essential residues for the catalytic function of 85-kDa cytosolic phospholipase A_2. *J. Biol. Chem.* **271**, 19225–19231 (1996).
14. Ong, W.-Y., Farooqui, T., Kokotos, G. & Farooqui, A. A. Synthetic and natural inhibitors of phospholipases A_2: Their importance for understanding and treatment of neurological disorders. *ACS Chem. Neurosci.* **6**, 814–831 (2015).
15. Magrioti, V. & Kokotos, G. Phospholipase A_2 inhibitors for the treatment of inflammatory diseases: a patent review (2010–present). *Expert Opin. Ther. Pat.* **23**, 333–344 (2013).
16. Kokotou, M. G., Limnios, D., Nikolaou, A., Psarra, A. & Kokotos, G. Inhibitors of phospholipase A_2 and their therapeutic potential: an update on patents (2012–2016). *Expert Opin. Ther. Pat.* **27**, 217–225 (2017).
17. Street, I. P. *et al.* Slow- and tight-binding inhibitors of the 85-kda human phospholipase A_2. *Biochemistry* **32**, 5935–5940 (1993).
18. Seno, K. *et al.* Pyrrolidine inhibitors of human cytosolic phospholipase A_2. *J. Med. Chem.* **43**, 1041–1044 (2000).
19. Eno, K. *et al.* Pyrrolidine inhibitors of human cytosolic phospholipase A_2. Part 2: synthesis of potent and crystallized 4-triphenylmethylthio derivative 'pyrrophenone'. *Bioorg. Med. Chem. Lett.* **11**, 587–590 (2001).
20. McKew, J. C. *et al.* Inhibition of cytosolic phospholipase A_2α: hit to lead optimization. *J. Med. Chem.* **49**, 135–158 (2006).
21. Lee, K. L. *et al.* Discovery of Ecopladib, an indole inhibitor of cytosolic phospholipase A_2α. *J. Med. Chem.* **50**, 1380–1400 (2007).
22. Lee, K. L. *et al.* Benzenesulfonamide indole inhibitors of cytosolic phospholipase A_2α: optimization of *in vitro* potency and rat pharmacokinetics for oral efficacy. *Bioorg. Med. Chem.* **16**, 1345–1358 (2008).
23. McKew, J. C. *et al.* Indole cytosolic phospholipase A_2α inhibitors: discovery and *in vitro* and *in vivo* characterization of 4-{3-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1h-indol-3-yl]propyl} benzoic acid, Efipladib. *J. Med. Chem.* **51**, 3388–3413 (2008).
24. http://ClinicalTrials.gov/ Identifier: NCT00396955.
25. http://ClinicalTrials.gov/ Identifier: NCT02795832.
26. Kokotos, G. *et al.* Novel 2-oxoamide inhibitors of human group IVA phospholipase A_2. *J. Med. Chem.* **45**, 2891–2893 (2002).

27. Kokotos, G. *et al.* Inhibition of group IVA cytosolic phospholipase A₂ by novel 2-oxoamides *in vitro*, in cells and *in vivo*. *J. Med. Chem.* **47**, 3615–3628 (2004).
28. Stephens, D. *et al.* Differential inhibition of group IVA and group VIA phospholipases A₂ by 2-oxoamides. *J. Med. Chem.* **49**, 2821–2828 (2006).
29. Yaksh, T. L. *et al.* Systemic and intrathecal effects of a novel series of phospholipase A₂ inhibitors on hyperalgesia and spinal prostaglandin E₂ release. *J. Pharmacol. Exper. Ther.* **316**, 466–475 (2006).
30. Six, D. A. *et al.* Structure-activity relationship of 2-oxoamide inhibition of group IVA cytosolic phospholipase A₂ and group V secreted phopholipase A₂. *J. Med. Chem.* **50**, 4222–4235 (2007).
31. Burke, J. E. *et al.* Location of inhibitors bound to group IVA phospholipase A₂ determined by molecular dynamics and deuterium exchange mass spectrometry. *J. Am. Chem. Soc.* **131**, 8083–8091 (2009).
32. Ludwig, J., Bovens, S., Brauch, C., Elfringhoff, A. S. & Lehr, M. Design and synthesis of 1-indol-1-yl-propan-2-ones as inhibitors of human cytosolic phospholipase A₂α. *J. Med. Chem.* **49**, 2611–2620 (2006).
33. Hess, M., Elfringhoff, A. S. & Lehr, M. 1-(5-Carboxy- and 5-carbamoylindol-1-yl)propan-2-ones as inhibitors of human cytosolic phospholipase A₂α: bioisosteric replacement of the carboxylic acid and carboxamide moiety. *Bioorg. Med. Chem.* **15**, 2883–2891 (2007).
34. Fritsche, A., Elfringhoff, A. S., Fabian, J. & Lehr, M. 1-(2-Carboxyindol-5-yloxy)propan-2-ones as inhibitors of human cytosolic phospholipase A₂α: synthesis, biological activity, metabolic stability, and solubility. *Bioorg. Med. Chem.* **16**, 3489–3500 (2008).
35. Bovens, S. *et al.* 1-(5-Carboxyindol-1-yl) propan-2-one inhibitors of human cytosolic phospholipase A₂α: Effect of substituents in position 3 of the indole scaffold on inhibitory potency, metabolic stability, solubility, and bioavailability. *J. Med. Chem.* **53**, 8298–8308 (2010).
36. Drews, A. *et al.* 1-(5-carboxyindol-1-yl)propan-2-one inhibitors of human cytosolic phospholipase A²α with reduced lipophilicity: Synthesis, biological activity, metabolic stability, solubility, bioavailability, and topical *in vivo* activity. *J. Med. Chem.* **53**, 5165–5178 (2010).
37. Kokotos, G. *et al.* Inhibition of group IVA cytosolic phospholipase A₂ by thiazolyl ketones *in vitro*, *ex vivo*, and *in vivo*. *J. Med. Chem.* **57**, 7523–7535 (2014).
38. Tomoo, T. *et al.* Design, synthesis, and biological evaluation 3-(1-aryl-1H-indol-5-yl)propanoic acids as new indole-based cytosolic phospholipase A₂α inhibitors. *J. Med. Chem.* **57**, 7244–7262 (2014).
39. Mouchlis, V. D., Bucher, D., McCammon, J. A. & Dennis, E. A. Membranes serve as allosteric activators of phospholipase A₂, enabling it to extract, bind, and hydrolyze phospholipid substrates. *PNAS* **112**, E516eE525 (2015).
40. Mouchlis, V. D. & Dennis, E. A. Membrane and inhibitor interactions of intracellular phospholipases A₂. *Adv. Biol. Regul.* **61**, 17–24 (2015).
41. Angelastro, M. R., Mehdi, S., Burkhart, J. P., Peet, N. P. & Bey, P. α-Diketone and α-keto ester derivatives of N-protected amino acids and peptides as novel inhibitors of cysteine and serine proteinases. *J. Med. Chem.* **33**, 11–13 (1990).
42. Peet, N. P. *et al.* Synthesis of peptidyl fluoromethyl ketones and peptidyl α-keto esters as inhibitors of porcine pancreatic elastase, human neutrophil elastase, and rat and human neutrophil cathepsin G. *J. Med. Chem.* **33**, 394–407 (1990).
43. Li, Z. *et al.* Peptide α-keto ester, α-keto amide, and α-keto acid inhibitors of calpains and other cysteine proteases. *J. Med. Chem.* **36**, 3472–3480 (1993).
44. Han, W., Hu, Z., Jiang, X. & Decicco, C. P. α-Ketoamides, α-ketoesters and α-diketones as HCV NS3 protease inhibitors. *Bioorg. Med. Chem. Lett.* **10**, 711–713 (2000).
45. Burkhart, J. P., Peet, N. P. & Bey, P. Oxidation of α-hydroxy esters to α-keto esters using the Dess-Martin periodinane reagent. *Tetrahedron Lett.* **29**, 3433–3436 (1988).
46. Baskakis, C. *et al.* Synthesis of polyfluoro ketones for selective inhibition of human phospholipase A₂ enzymes. *J. Med. Chem.* **51**, 8027–8037 (2008).
47. Kokotos, G. *et al.* Potent and selective fluoroketone inhibitors of group VIA calcium-independent phospholipase A₂. *J. Med. Chem.* **53**, 3602–3610 (2010).
48. Magrioti, V. *et al.* New potent and selective polyfluoroalkyl ketone inhibitors of GVIA calcium-independent phospholipase A₂. *Bioorg. Med. Chem.* **21**, 5823–5829 (2013).
49. Mouchlis, V. D. *et al.* Development of potent and selective inhibitors for group VIA calcium-independent phospholipase A₂ guided by molecular dynamics and structure-activity relationships. *J. Med. Chem.* **59**, 4403–4414 (2016).
50. Lipinski, C., Lombardo, F., Dominy, B. & Feeney, P. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv. Drug Deliv. Rev.* **23**, 3–25 (1997).
51. Six, D. A. & Dennis, E. A. The expanding superfamily of phospholipase A₂ enzymes: classification and characterization. *Biochim. Biophys. Acta* **1488**, 1–19 (2000).
52. Humes, J. L. *et al.* The diminished production of arachidonic acid oxygenation products by elicited mouse peritoneal macrophages: possible mechanisms. *J. Immunol.* **124**, 2110–2116 (1980).
53. Funk, C. D. Prostaglandins and leukotrienes: advances in eicosanoid biology. *Science* **294**, 1871–1875 (2001).
54. Simmons, D. L., Botting, R. M. & Hla, T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. *Pharmacol. Rev.* **56**, 387–437 (2004).
55. Smith, W. L., DeWitt, D. L. & Garavito, R. M. Cyclooxygenases: structural, cellular, and molecular biology. *Annu. Rev. Biochem.* **69**, 145–182 (2000).
56. Norris, P. C., Reichart, D., Dumlao, D. S., Glass, C. K. & Dennis, E. A. Specificity of eicosanoid production depends on the TLR-4-stimulated macrophage phenotype. *J. Leukoc. Biol.* **90**, 563–574 (2011).
57. Vasilakaki, S. *et al.* Development of a potent 2-oxoamide inhibitor of secreted phospholipase A₂ guided by molecular docking calculations and molecular dynamics simulations. *Bioorg. Med. Chem.* **24**, 1683–1695 (2016).
58. Mori, K. & Funaki, Y. Synthesis of (4E,8E,2S,3R,2′R)-N-2′-hydroxyhexadecanoyl-9-methyl-4,8-sphingadiemine, the ceramide portion of the fruiting-inducing cerebroside in a basidiomycete schizophyllum commune, and its (2R,3S)-isomer. *Tetrahedron.* **41**, 2369–2377 (1985).
59. Hell, C. & Jordanoff, C. Ueber neue derivate palmitinsäuse. *Ber. Dtsch. Chem. Ges.* **24**, 936–943 (1891).
60. Antonopoulou, G. *et al.* 2-Oxoamide inhibitors of cytosolic group IVA phospholipase A₂ with reduced lipophilicity. *Bioorg. Med. Chem.* **24**, 4544–4554 (2016).
61. Lin, Z. *et al.* Chiral surfactant-type catalyst: Enantioselective reduction of long-chain aliphatic ketoesters in water. *J. Org. Chem.* **80**, 4419–4429 (2015).
62. Valcani, U. *et al.* New potential immunoenhancing compounds. Synthesis and pharmacological evaluation of new long-chain 2-amido-2-deoxy-D-glucose derivatives. *Arzneimittel-Forschung/Drug Res.* **39**, 1190–1195 (1989).
63. Friesner, R. A. *et al.* Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. *J. Med. Chem.* **49**, 6177–6196 (2006).
64. Wang, Y., Armando, A. M., Quehenberger, O., Yan, C. & Dennis, E. A. Comprehensive ultra-performance liquid chromatographic separation and mass spectrometric analysis of eicosanoid metabolites in human samples. *J. Chromatogr. A* **1359**, 60–69 (2014).

Acknowledgements

Author Contributions

G.K. and E.A.D. contributed to conception and design of the work, interpreted the data, and wrote the manuscript. M.G.K. contributed to *in vitro* assay experiments, data analyses, and manuscript preparation and editing. G.G., V.M., G.Koutoulogenis, E.B. contributed to synthesis. D.L., V.D.M. and B.S. contributed to *in vitro* assay experiments. A.N. contributed to macrophage eicosanoid production experiments.

Additional Information

Competing Interests: The authors declare that they have no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.